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Metformin hydrochlorideAbstract The study was aimed at developing extended release matrix tablets of poorly water-
soluble diclofenac sodium and highly water-soluble metformin hydrochloride by direct compression
using cashew gum, xanthan gum and hydroxypropylmethylcellulose (HPMC) as release retardants.
The suitability of light grade cashew gum as a direct compression excipient was studied using the
SeDeM Diagram Expert System. Thirteen tablet formulations of diclofenac sodium (100 mg)
and metformin hydrochloride (200 mg) were prepared with varying amounts of cashew gum,
xanthan gum and HPMC by direct compression. The ﬂow properties of blended powders and
the uniformity of weight, crushing strength, friability, swelling index and drug content of com-
pressed tablets were determined. In vitro drug release studies of the matrix tablets were conducted
in phosphate buffer (diclofenac: pH 7.4; metformin: pH 6.8) and the kinetics of drug release was
determined by ﬁtting the release data to ﬁve kinetic models. Cashew gum was found to be suitable
for direct compression, having a good compressibility index (ICG) value of 5.173. The diclofenac
and metformin matrix tablets produced generally possessed fairly good physical properties.
Tablet swelling and drug release in aqueous medium were dependent on the type and amount of
release retarding polymer and the solubility of drug used. Extended release of diclofenac (24 h)
and metformin (8–12 h) from the matrix tablets in aqueous medium was achieved using various
blends of the polymers. Drug release from diclofenac tablets ﬁtted zero order, ﬁrst order or
Higuchi model while release from metformin tablets followed Higuchi or Hixson-Crowell model.
Development of extended release matrix tablets of two drugs 83The mechanism of release of the two drugs was mostly through Fickian diffusion and anomalous
non-Fickian diffusion. The study has demonstrated the potential of blended hydrophilic polymers
in the design and optimization of extended release matrix tablets for soluble and poorly soluble
drugs by direct compression.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hydrophilic polymers such as guar gum, pectin, chitosan,
cashew gum, xanthan gum, HPMC and microcrystalline cellu-
lose are pharmaceutical excipients which have been utilized
individually or in blends to design hydrophilic matrix tablets
to achieve controlled drug delivery (Maciel et al., 2006;
Chivate et al., 2008; Nussinovitch, 2009; Vohra et al., 2012;
Ali et al., 2013; Baviskar et al., 2013). Controlled-release
dosage forms generally have reduced frequency of dosing,
increased compliance, increased therapeutic effect, reduced
side-effects, improved tolerability and reduced cost of treat-
ment (Das and Das, 2003; Kamboj et al., 2009). Blending dif-
ferent hydrophilic polymers improves the physicochemical and
release modifying properties of the resultant polymer leading
to the design and formation of an optimized controlled-release
product (Ofori-Kwakye et al., 2013) and the proper selection
of polymers can help control the release proﬁle of drugs
(Fung and Saltzman, 1997). Hydrophilic matrix systems
undergo swelling followed by gel formation, erosion and
dissolution in aqueous media. In addition, such systems can
sustain high drug loading and the excipients used are inexpen-
sive and generally regarded as safe. They may however require
optimal rate-controlling polymers for different active pharma-
ceutical ingredients (API’s) and there could be challenges with
scale-up of manufacture (Aulton, 2007).
Hydrophilic matrix tablets can be manufactured by wet
granulation or direct compression techniques (Colombo
et al., 2000). Direct compression is a simple technique of
tableting a blend of powdered ingredients without granule for-
mation or agglomeration process (Thakkar et al., 2009;
Thoorens et al., 2014) and involves two sequential operations
of powder mixing and tableting. The procedure requires the
use of API’s and or excipients with good ﬂow and compress-
ibility. As there is no involvement of heat and moisture in
the process, direct compression is well-suited for heat and
moisture-sensitive drugs and also enhances product stability
(Aulton, 2007). The small number of operations involved in
direct compression makes for reduced production cost making
direct compression the most economical technique of manu-
facturing large batches of tablets (Thoorens et al., 2014). The
major challenges associated with direct compression caused
by the use of API’s and excipients with poor physical attributes
include poor ﬂowability of powder blends, variability in tablet
weight, poor content uniformity, tablets with poor mechanical
strength and poor dissolution properties (Hentzschel et al.,
2012; Thoorens et al., 2014).
Diclofenac sodium is a poorly water soluble (pKa = 4),
Biopharmaceutics Classiﬁcation System (BCS) class II (low
solubility and high permeability), non-steroidal anti-in-
ﬂammatory drug. It is commonly used in the treatment of mild
to moderate post-operative or post-traumatic pain, menstrualpain and endometritis (Dastidar et al., 2000). Extended release
diclofenac formulations are required for the treatment of
chronic conditions such as rheumatoid arthritis, osteoarthritis,
chronic pain, ankylosing spondylitis and actinic keratosis.
Metformin hydrochloride is a highly water soluble
(>300 mg/ml at 25 C; pKa = 2.8 and 11.5), BCS class III
(high solubility and low permeability) oral anti-diabetic drug
in the biguanide class. It is a ﬁrst line drug in the treatment
of type-2 diabetes. Extended release metformin is needed for
the long-term management and control of type-2 diabetes
mellitus.
The aim of the current study was to design extended release
oral matrix tablets of diclofenac sodium and metformin
hydrochloride using varying blends of three hydrophilic poly-
mers. The objective was to enhance the drug release modifying
properties of the polymers leading to the formation of opti-
mized formulations of the two model drugs with different
water solubilities.
2. Materials and methods
2.1. Materials
Metformin HCl was a gift from Ernest Chemist Ltd. (Accra,
Ghana). Diclofenac sodium BP was sourced from Hubei
Prosperity Galaxy Chemical Co. Ltd. (China). Xanthan gum
(SHL_PHXG980) was obtained from Luckystar Additives
Co. Ltd. (Hong Kong). Microcrystalline cellulose (ACCEL
101) was sourced from Lavina Pharmaceuticals Pvt. Ltd.,
India. Glucophage and voltaren retard were purchased
from retail pharmacies in Kumasi, Ghana. Potassium dihydro-
gen orthophosphate was obtained from Central Drug House
Ltd. (New Delhi, India) and phosphoric acid and diethyl ether
from Pokupharma Ltd. (Kumasi, Ghana). HPMC (Methocel
E-15), magnesium stearate, ethanol, sodium hydroxide pellets,
and hydrochloric acid were obtained from the Chemical store
of the Pharmaceutics Department, KNUST, (Kumasi,
Ghana). All other reagents used were of analytical grade.
Crude cashew gum was collected from Bodokrom cashew plan-
tation (Eastern Region, Ghana) and manually sorted into light
and dark grades and the light grade cashew gum was puriﬁed as
described elsewhere (Ofori-Kwakye et al., 2010). The puriﬁed
light grade cashew gum (yield: 75.19%; moisture content
5.25 ± 0.35%, size range: 50–425 lm; swelling capacity: 3.33
(distilled water), 3.83 (phosphate buffer pH 6.8), 3.91 (phos-
phate buffer pH 7.4) (Mfoafo, 2013)) was employed as a direct
compression excipient in the preparation of matrix tablets.
2.2. Preparation of blended powders
The compositions of various diclofenac sodium and metformin
HCl matrix tablet formulations are presented in Tables 1 and 2,
Table 1 Composition of different formulations of diclofenac sodium matrix tablets (500 mg tablet).
Formulation Diclofenac
sodium (mg)
Cashew
gum (mg)
Xanthan
gum (mg)
HPMC
(mg)
Microcrystalline
cellulose (mg)
Magnesium
stearate (mg)
D1 100 200 – – 195 5
D2 100 100 – – 295 5
D3 100 150 50 – 195 5
D4 100 100 100 – 195 5
D5 100 50 150 – 195 5
D6 100 – 200 – 195 5
D7 100 150 – 50 195 5
D8 100 100 – 100 195 5
D9 100 50 – 150 195 5
D10 100 – – 200 195 5
D11 100 100 50 50 195 5
D12 100 50 100 50 195 5
D13 100 50 50 100 195 5
Table 2 Composition of different formulations of metformin hydrochloride matrix tablets (600 mg tablet).
Formulation Metformin
HCl (mg)
Cashew
gum (mg)
Xanthan
gum (mg)
HPMC
(mg)
Microcrystalline
cellulose (mg)
Magnesium
stearate (mg)
M1 200 100 – – 294 6
M2 200 200 – – 194 6
M3 200 – 100 – 294 6
M4 200 – 200 – 194 6
M5 200 – – 100 294 6
M6 200 – – 200 194 6
M7 200 150 50 - 194 6
M8 200 100 100 - 194 6
M9 200 100 50 50 194 6
M10 200 150 – 50 194 6
M11 200 100 – 100 194 6
M12 200 50 100 50 194 6
M13 200 50 50 100 194 6
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sodium, microcrystalline cellulose, cashew gum, xanthan gum
and HPMC were thoroughly mixed geometrically in a mortar
for 15 min. The same procedure was employed in blending
metformin HCl, microcrystalline cellulose, cashew gum,
xanthan gum and HPMC. The powder blends prepared were
lubricated with magnesium stearate for 2 min and stored for
subsequent analysis and direct compression.
2.3. Bulk density measurements of cashew gum and blended
powders
Ten grams of puriﬁed cashew gum was weighed and poured
through a funnel into a 100 ml measuring cylinder. The cylin-
der was lightly tapped twice to collect all the granules sticking
on the wall of the cylinder and the initial volume, Vo was
recorded. The cylinder was tapped from a height of 2.0 cm
on a wooden bench top to a constant volume of powder
denoted as Vf. The initial density was calculated as the initial
bulk density, Do = mass/Vo. The ﬁnal density was calculated
as the ﬁnal bulk density or tapped bulk density, Df = mass/Vf.
The ratio Df/Do was calculated as the Hausner ratio while
Carr’s index was calculated as (Df  Do/Df) · 100% and the
interparticle porosity was calculated as [(Df  Do)/(Df ·Do)] (Aulton, 2007). The procedures were repeated in
determining the Hausner ratio, Carr index and interparticle
porosity of blended powders of diclofenac and metformin
formulations.
2.4. Angle of repose of cashew gum and blended powders
The angles of repose (h) of puriﬁed cashew gum and blended
powders of diclofenac and metformin HCl formulations were
determined using the ﬁxed height method (Aulton, 2007).
Each powder formulation was allowed to ﬂow freely from a
funnel at a ﬁxed height onto a horizontal surface to form a
cone. The base of the cone was marked and the height of the
oriﬁce of the funnel from the horizontal surface was measured.
The height of the cone was measured and the angle of repose
was calculated from the height of the cone (h) and the radius
(r) of its base using the equation, h= tan1 h/r.
2.5. Determination of suitability of cashew gum for direct
compression
Eight out of the twelve physicochemical tests (minimum relia-
bility) used in the SeDeM Diagram method (Pe´rez-Lozano
et al., 2006; Sun˜e´-Negre et al., 2008; Sun˜e-Negre et al., 2011)
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its suitability for direct compression. The Dimensional
Parameters (bulk density and tapped density),
Compressibility Parameters (inter-particle porosity and
Carr’s index), Flowability Parameters (Hausner ratio and
angle of repose), Stability Parameter (loss on drying) and
Dosage Parameter (% particle < 75 lm) of light grade cashew
gum were determined using pharmacopoeial and other
accepted experimental procedures. Each result was converted
to a radius on a 0–10 scale and an eight-sided polygon drawn
from it after which the Parameter Index (nPP 5/nPt, where
nPP 5 = number of parameters that have values equal to
or greater than 5, and nPt = total number of parameters
studied), Parameter Proﬁle Index (average of radii of all
parameters examined) and Reliability Factor (ratio of area
of polygon and area of circle) were calculated (Sun˜e-Negre
et al., 2011). The Good Compressibility Index (IGC) which
is a measure of the suitability of a powdered material for direct
compression was calculated by multiplying the Parameter
Proﬁle Index and the Reliability Factor. Powders with IGC
valuesP 5 are considered suitable for use in direct compres-
sion (Pe´rez-Lozano et al., 2006; Sun˜e´-Negre et al., 2008;
Aguilar-Dı´az et al., 2009).
2.6. Direct compression of tablets
Thirteen different diclofenac blended powder formulations
were directly compressed into matrix tablets each containing
100 mg diclofenac with a nominal tablet weight of 500 mg,
using a DP 30 Single-punch tablet Press (Pharmao Industries
Co. Ltd., India) ﬁtted with a concave punch and die set. The
procedure was repeated to directly compress thirteen
metformin HCl powder formulations into matrix tablets each
containing 200 mg metformin with a nominal tablet weight
of 600 mg.
2.7. Evaluation of tablet properties
Quality parameters of diclofenac sodium and metformin HCl
matrix tablets, namely tablet thickness, uniformity of weight,
crushing strength and friability were evaluated. A vernier cali-
per was used to measure the thickness of ﬁve (5) matrix tablets
from each batch and the mean and standard deviation
determined. The uniformity of weight of twenty tablets was
determined according to the British Pharmacopoeia (2012)
method. The crushing strength of ten tablets was determined
by diametrical compression using a dr Schleuniger Hardness
Tester (model 5Y, Pharmatron, Switzerland). All measure-
ments were made in triplicate and the average calculated.
The friability of the tablets was determined with an Erweka fri-
abilator (Type TA20, Heusenstamm, Germany) according to
the procedure of the United States Pharmacopoeia and
National Formulary (2007). The ratio of the crushing strength
to friability of a batch of tablets was determined as the crush-
ing strength friability ratio (CSFR).
2.8. Determination of swelling index
The swelling behavior of diclofenac sodium and metformin
HCl matrix tablets was determined at 37 ± 0.5 C in phos-
phate buffer pH 7.4 and phosphate buffer pH 6.8, respectively,over 18 h. Five tablets from each formulation were individu-
ally kept in a petri dish containing 50 ml of the buffer solution.
At the end of the stipulated period the tablet was removed,
blotted with a tissue paper and weighed. The extent of swelling
was calculated as: Swelling index = [(Mt Mo)/Mo] · 100,
where, Mt and Mo are the weight of tablet at time = t and
time = 0, respectively.
2.9. Determination of drug content
The amount of diclofenac sodium in twenty randomly selected
diclofenac sodium matrix tablets was determined
spectrophotometrically (T90 UV/VIS Spectrometer, PG
Instruments Ltd., England) at 276 nm as reported elsewhere
(Ofori-Kwakye et al., 2013). Also, the amount of metformin
HCl in ten randomly selected metformin HCl matrix tablets
was determined spectrophotometrically at 233 nm
(Narasimharao et al., 2011).
2.10. In vitro drug release studies
In vitro drug release studies were carried out using Voltaren
retard and Glucophage as reference tablets for diclofenac
and metformin, respectively. A USP type II dissolution appa-
ratus (paddle method) (Erweka dissolution machine, Type
DT6, GmbH, Heusenstamm, Germany) was used for the stud-
ies. The test conditions for diclofenac sodium matrix tablets
were as follows: dissolution medium: 900 ml phosphate buffer
pH 7.4; paddle speed: 50 rpm; temperature: 37 ± 0.5 C; sam-
pling period: 24 h. The same test conditions were used for met-
formin HCl matrix tablets except that the pH, paddle speed
and sampling period were 6.8, 100 rpm and 12 h, respectively.
At speciﬁed time intervals, 10 ml samples were withdrawn and
replaced with the same volume of fresh dissolution medium
maintained at 37 ± 0.5 C. The withdrawn samples were
rapidly ﬁltered using a Whatman ﬁlter paper and diluted
appropriately with the dissolution medium. The diluted ﬁl-
trates were analyzed by UV spectrophotometry (T90 UV/VIS
Spectrometer, PG Instruments Ltd., England) at 276 nm and
233 nm for diclofenac sodium and metformin HCl samples
respectively using the respective dissolution media as reference
solutions. A 1 cm quartz cuvette was used throughout the
study. The amount of diclofenac in diclofenac sodium matrix
tablets was determined using regression data (y= 345.51x
+ 0.1929, R2 = 0.9983) obtained from calibration plot of
diclofenac in phosphate buffer pH 7.4 (0.75–2.5 mg/100 ml).
The amount of metformin in metformin HCl matrix tablets
was determined using regression data (y= 743x+ 0.2872,
R2 = 0.9947) obtained from a calibration plot of metformin
in phosphate buffer pH 6.8 (0.2–0.6 mg/100 ml). From these,
plots of percentage drug released from the tablet formulations
(mean ± S.D., n= 3) versus time were established.
2.11. Kinetics of drug release
The kinetics of drug release from the matrix tablets was deter-
mined by ﬁtting the appropriate drug release data to zero order
(Varelas et al., 1995), ﬁrst order (Gibaldi and Feldman, 1967;
Wagner, 1969), Higuchi equation (Higuchi, 1963), Hixson-
Crowell equation (Hixson and Crowell, 1931) and the
Korsmeyer-Pepas model (Korsmeyer et al., 1983; Peppas, 1985).
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In Q ¼ In Q0 þ k1t ðFirst orderÞ
Q ¼ kHt1=2 ðHiguchi modelÞ
Q
1=3
0 Q1=3R ¼ kst ðHixson-Crowell modelÞ
Q=QT ¼ kkptnðKorsmeyer-Peppas modelÞ
where Q is amount of drug release at time t, Q0 is the initial
amount of drug, QR is the amount of drug remaining at time
t, and QT is the total amount of drug release. k0, k1, kH, ks
and kkp are the kinetic constants for zero order, ﬁrst order,
Higuchi, Hixson-Crowell and Korsmeyer-Peppas models,
respectively, and n is the release exponent.
2.12. Statistical analysis
The drug release data generated for the two drugs were sub-
jected to one-way analysis of variance (ANOVA) followed
by Tukey’s multiple comparison test using GraphPad Prism
version 5.00 for Windows (GraphPad Software, San Diego
California, USA, www.graphpad.com). Differences between
batches of tablets were considered signiﬁcant when p< 0.5.
3. Results and discussions
Light grade cashew gum obtained locally in Ghana was puri-
ﬁed and the suitability of the powder as a direct compression
excipient was evaluated based on the SeDeM
Diagram Expert System. The SeDeM method uses twelve
parameters to examine whether or not a powder is suitable
for direct compression and a minimum of eight parameters
can be used (Pe´rez-Lozano et al., 2006). Table 3 presents the
physicochemical properties of puriﬁed cashew gum and the
derived data based on eight parameters of the SeDeM
Expert System. The SeDeM diagram is a useful tool used in
evaluating the physical characteristics of pharmaceutical
excipients (Aguilar-Dı´az et al., 2009), and to determine the
suitability of API’s and excipients for direct compression.
The technique is also used in determining the amount of excipi-
ent required for the compression of an API which is not apt forTable 3 Physicochemical properties of cashew gum and
derived data based on the SeDeM Diagram Expert System.
Parameter Experimental
results
Limit
value
(V)
Factor
applied
to V
Radius
Bulk density (g/ml) 0.71 0–1 10V 7.1
Tapped density (g/ml) 0.83 0–1 10V 8.3
Interparticle porosity 0.204 0–1.2 10V/1.2 1.7
Carr’s index 14.46 0–50 V/5 2.9
Hausner ratio 1.17 3–1 (30–10V)/2 9.15
Angle of repose () 38.7 50–0 10  (V/5) 2.26
Loss on drying (%) 5.25 10–0 10  V 4.75
Particles < 75 lm (%) 0.9 50–0 10  (V/5) 9.82
Parameter Index (PI) = 0.5; Parameter proﬁle index = 5.7475;
Reliability factor = 0.9; Good compressibility index = 5.173.direct compression. According to the SeDeM model, an API
or excipient is suitable for direct compression when the good
compressibility index (IGC) determined from the SeDeM
equation isP5.0 (Sun˜e-Negre et al., 2011). The IGC obtained
for cashew gum in the current study was 5.173, indicating its
suitability as a direct compression excipient.
Thirteen different powder formulations of diclofenac
sodium matrix tablets and metformin HCl matrix tablets were
prepared employing varying ratios of cashew gum, xanthan
gum and HPMC as drug release retardants/modiﬁers. The
objective was to develop matrix tablet formulations of the
two drugs having the requisite extended release characteristics.
The ﬂowability of the blended powders was characterized
using indirect methods of Hausner ratio, Carr index and angle
of repose (Staniforth, 2002). Hausner ratio values >1.6 indi-
cate poor ﬂow properties while values 1.25 demonstrate good
ﬂow properties. Carr compressibility index 616% is indicative
of good ﬂow properties while values > 23% exhibit poor
ﬂowability. In terms of angle of repose, values closer to 25
have good ﬂow properties while values closer to 40 have poor
ﬂow properties. Blended powder formulations of diclofenac
sodium had Hausner ratio, Carr index, interparticle porosity
and angle of repose values of 1.42–1.58, 29.58–36.62%,
0.592–0.833 and 28.5–42.3, respectively. While Carr index val-
ues of diclofenac sodium powder formulations appeared to
indicate poor ﬂow, the Hausner ratio and angle of repose
values showed the blended powders in general possessed
average to good ﬂowability. Blended powder formulations of
metformin had Hausner ratio (1.31–1.49), Carr index (23.38–
35.06%), interparticle porosity (0.396–0.730), and angle of
repose (29.2–32.3). Metformin HCl powder formulations gen-
erally possessed good ﬂow properties and exhibited lower
interparticle porosity than diclofenac formulations.
Magnesium stearate, a glidant was employed to enhance the
ﬂowability of the blended powders for direct compression.
Microcrystalline cellulose (MCC) was employed in the
formulation of matrix tablets of the two drugs because of its
versatility as a direct compression excipient. MCC improves
the compactibility or tabletability of the compression mix of
tablet formulations (Thoorens et al., 2014). Tables 4 and 5
show the physical characteristics of diclofenac sodium
(100 mg) and metformin HCl matrix tablets (200 mg),
respectively. The average weight of diclofenac tablets ranged
from 496.3 to 519.5 mg while that of metformin tablet was
595.3–627.4 mg. All tablet formulations of the two drugs
passed the British Pharmacopoeia (2012) uniformity of weight
test (<2 tablets ± 5% mean weight, none ± 10% mean
weight, n= 20). Tablets of the two drugs exhibited good
mechanical strength with crushing strength valuesP 39.2 N,
except diclofenac formulation D4 and metformin formulation
M7. The friability test measures the ability of tablets to with-
stand abrasion and chipping during handling, packaging and
transportation and should not exceed 1%. Five diclofenac
tablet formulations, D1, D2, D4, D5 and D11 and ﬁve met-
formin tablet formulations M1, M3, M5, M7 and M13 failed
the friability test.
The crushing strength-friability ratio (CSFR) is a parame-
ter used to evaluate the quality of tablets (Odeku, 2005;
Bakre and Jaiyeoba, 2009). The CSFR is a ratio of tablet
strength (crushing strength) and tablet weakness (friability)
and high CSFR values are indicative of tablets of high quality.
The CSFR values of diclofenac tablets ranged from 4.72 to
Table 4 Physical characteristics of diclofenac sodium matrix tablets prepared by direct compression.
Formulation Weight (mg) Thickness (mm) Crushing strength (N) Friability (%) CSFR Drug content (%)
D1 506.0 ± 10.0 5.06 ± 0.20 44.5 ± 12.8 3.1 14.35 90.34 ± 1. 29
D2 519.5 ± 10.2 4.91 ± 0.06 66.3 ± 19.6 1.5 44.20 80.99 ± 2.34
D3 508.8 ± 9.5 5.12 ± 0.08 114.6 ± 17.5 0.7 163.71 89.75 ± 4.32
D4 499.3 ± 10.0 5.24 ± 0.12 28.3 ± 8.2 6.0 4.72 59.25 ± 3.88
D5 496.3 ± 8.4 5.39 ± 0.11 65.3 ± 16.9 3.1 21.06 85.23 ± 2.81
D6 498.4 ± 10.1 5.18 ± 0.09 102.6 ± 31.0 0.7 146.57 60.33 ± 4.32
D7 503.5 ± 10.0 5.13 ± 0.12 85.8 ± 17.1 0.8 107.25 92.59 ± 1.99
D8 508.9 ± 19.3 5.06 ± 0.11 112.8 ± 19.0 0.7 161.14 95.51 ± 2.65
D9 510.6 ± 10.4 5.72 ± 0.11 81.8 ± 16.1 0.8 102.25 96.51 ± 3.22
D10 510.7 ± 8.7 5.59 ± 0.08 108.2 ± 38.1 0.7 154.57 98.20 ± 1.29
D11 500.2 ± 9.1 5.40 ± 0.13 56.6 ± 14.9 1.5 37.73 91.17 ± 3.29
D12 501.1 ± 11.1 5.26 ± 0.08 91.5 ± 1.1 0.9 101.67 90.80 ± 2.73
D13 498.3 ± 7.9 5.18 ± 0.13 108.9 ± 20.9 0.9 121.00 99.80 ± 1.20
Table 5 Physical characteristics of metformin hydrochloride matrix tablets prepared by direct compression.
Formulation Weight (mg) Thickness (mm) Crushing strength (N) Friability (%) CSFR Drug content (%)
M1 619.2 ± 20.0 6.92 ± 0.12 65.9 ± 21.3 1.30 50.69 106.64 ± 2.73
M2 627.4 ± 17.2 6.73 ± 0.16 136.5 ± 21.6 0.47 290.43 96.24 ± 2.55
M3 601.7 ± 16.0 7.05 ± 0.17 41.0 ± 10.0 2.71 15.13 96.38 ± 1.78
M4 598.8 ± 15.3 6.68 ± 0.33 193.0 ± 38.1 0.70 275.71 90.12 ± 3.20
M5 602.2 ± 18.1 7.13 ± 0.32 65.3 ± 33.6 1.34 48.73 96.18 ± 1.94
M6 596.2 ± 10.0 7.06 ± 0.04 128.7 ± 17.7 0.64 201.09 99.15 ± 3.38
M7 612.6 ± 9.7 7.31 ± 0.06 32.7 ± 8.6 3.23 10.12 103.29 ± 2.94
M8 616.8 ± 16.9 6.66 ± 0.04 97.5 ± 18.2 0.75 130.00 104.68 ± 1.78
M9 602.2 ± 8.7 6.41 ± 0.09 180.3 ± 18.1 0.67 269.10 105.17 ± 4.23
M10 595.3 ± 7.8 6.68 ± 0.02 80.4 ± 18.7 0.46 174.78 99.27 ± 2.56
M11 600.0 ± 10.1 6.83 ± 0.20 139.6 ± 20.3 0.61 228.85 106.35 ± 2.44
M12 620.4 ± 9.0 7.11 ± 0.14 56.4 ± 21.7 0.84 67.14 109.30 ± 1.98
M13 615.8 ± 15.3 6.93 ± 0.22 51.9 ± 31.3 2.72 19.08 102.93 ± 3.26
Figure 1 Swelling index of extended release diclofenac sodium
matrix tablets in phosphate buffer pH 7.4 (mean ± S.D, n= 5).
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290.43. Metformin tablet formulations generally had higher
CSFR values than diclofenac tablets and could indicate tablets
of higher quality. The diclofenac content in diclofenac matrix
tablets ranged from 59.25% to 99.80% while metformin
content in metformin HCl matrix tablets was 90.12–
109.30%. Diclofenac and metformin tablets should contain
90–110% diclofenac and 95–105% metformin of the drug con-
tent on assay (USP, 2007). Nine diclofenac tablet formulations
satisﬁed this pharmacopoeia speciﬁcation except formulations
D2, D4, D5 and D6 which were underdose. Also, nine met-
formin tablet formulations conformed to the pharmacopoeia
speciﬁcation but while M1, M11 and M12 were overdose,
M4 was underdose. The failure of some tablet formulations
to pass the assay test could be due to improper ﬂow of the
blended powders as well as non-uniform ﬁlling of the die.
Figs. 1 and 2 are plots of swelling indices of diclofenac
tablets in phosphate buffer pH 7.4 and metformin matrix
tablets in phosphate buffer pH 6.8, respectively, over 18 h.
The swelling index of diclofenac tablet formulations ranged
from 32.29% to 291.85% while that of metformin ranged from
28.0% to 184.09%. Tablet formulations of the two drugs con-
taining xanthan gum alone or in combination with other
release retardants exhibited high swelling indices (D3, D4,
D5, D6, D11, D12, D13 and M3, M4, M7, M8, M9, M12,
M13). On the other hand, formulations containing HPMCalone or in combination with cashew gum exhibited low swel-
ling indices (D7, D8, D9, D10 and M5, M6, M10, M11). The
swelling index is used to characterize the hydrophilic character
of formulations. The polymers employed in the preparation of
the matrix tablets are hydrophilic in nature and in aqueous
media the tablets absorb water, swell and increase in size.
The swelling index is an indication of the ability of the polymer
material used to absorb water while maintaining the integrity
of the tablets.
Figure 2 Swelling index of extended release metformin
hydrochloride matrix tablets in phosphate buffer pH 6.8
(mean ± S.D, n= 5).
Figure 3 Dissolution proﬁles of extended release diclofenac
sodium matrix tablets in phosphate buffer pH 7.4 (mean ± S.D,
n= 3), (a) formulations D1-D6, ST-D, (b) formulations D7-D13,
ST-D.
Figure 4 Dissolution proﬁles of extended release metformin
hydrochloride matrix tablets in buffer pH 6.8 (mean ± S.D,
n= 3), (a) formulations M1-D6, ST-M, (b) formulations M7-
M13, ST-M.
88 K. Ofori-Kwakye et al.Figs. 3 and 4 are release proﬁles of diclofenac and
metformin matrix tablets, respectively, in comparison with
the reference drug samples. Extended drug release proﬁles
for 24 h were obtained for diclofenac matrix tablets while
extended release for 8–12 h was achieved for metformin matrix
tablets. Thus, the water insoluble diclofenac achieved a longer
drug release than the water-soluble metformin, conﬁrming the
ﬁnding that more release-retarding polymer is required to sus-
tain drug release from water soluble drugs than water insolubledrugs (Chakraborty et al., 2009). Drug solubility is one of the
key factors considered in the fabrication of controlled release
delivery systems (Sudha et al., 2010). Drug release from
diclofenac tablet formulations D2, D3, D4, D5, D6, D11,
D12 and D13 was signiﬁcantly different (p< 0.05) from volta-
ren retard, the reference drug, while drug release from D1, D7,
D8, D9 and D10 was similar (p> 0.05) to that of Voltaren
retard. Drug release from the various metformin matrix tablet
formulations was similar (p> 0.05) to that of Glucophage SR,
the reference drug.
Release kinetics is an essential aspect of drug formulation
development and kinetic data are also employed in setting
in vivo–in vitro correlation (IVIVC) of dosage forms
(Thakkar et al., 2009). Tables 6 and 7 present the kinetics of
release of extended release diclofenac and metformin matrix
tablets, respectively. The release kinetics was evaluated by ﬁt-
ting the drug release data to ﬁve kinetic models. The kinetic
model with the highest correlation coefﬁcient value (R2) was
selected as the model that best described the dissolution data.
Drug release from diclofenac and metformin tablet formula-
tions followed zero order, ﬁrst order, Higuchi or Hixson-
Crowell models but none followed the Korsmeyer-Peppas
model. In general, most of the poorly water-soluble diclofenac
tablet formulations followed the ﬁrst order (R2 = 0.9845–
0.9964, for D1, D3, D12, D13) or Higuchi kinetic model
(R2 = 0.9187–0.9908, for D2, D7, D8, D9, D10, D11, ST-D)
while water-soluble metformin tablet formulations followed
Higuchi (R2 = 0.7937–0.9618, for M1, M2, M3, M5, M9,
Table 6 Release kinetics of diclofenac sodium matrix tablets in phosphate buffer pH 7.4 at 37 C.
Formulation Zero order R2 First order R2 Higuchi R2 Hixson-Crowell R2 Korsmeyer-Peppas R2
D1 0.9593 0.9947 0.9897 0.9889 0.9337
D2 0.9461 0.9748 0.9855 0.9667 0.9566
D3 0.9853 0.9964 0.9738 0.9939 0.8863
D4 0.9657 0.9683 0.9330 0.9685 0.9338
D5 0.9886 0.9862 0.9453 0.9887 0.9821
D6 0.9696 0.9634 0.9201 0.9666 0.9614
D7 0.9417 0.9819 0.9908 0.9718 0.9208
D8 0.9223 0.9690 0.9883 0.9548 0.9742
D9 0.9349 0.9806 0.9895 0.9703 0.8598
D10 0.9013 0.9654 0.9807 0.9479 0.9573
D11 0.9558 0.9696 0.9848 0.9682 0.8391
D12 0.9786 0.9845 0.9624 0.9829 0.9290
D13 0.9806 0.9954 0.9827 0.9903 0.9521
ST-D 0.7831 0.8953 0.9187 0.8655 0.8964
ST-D= Voltaren retard (standard diclofenac tablet).
Table 7 Release kinetics of metformin hydrochloride matrix tablets in phosphate buffer pH 6.8 at 37 C.
Formulation Zero order R2 First order R2 Higuchi R2 Hixson-Crowell R2 Korsmeyer-Peppas R2
M1 0.6775 0.6839 0.8008 0.6807 0.4395
M2 0.6682 0.6642 0.8019 0.6712 0.5701
M3 0.6726 0.6795 0.7937 0.6703 0.4326
M4 ND ND ND ND ND
M5 0.7511 0.8664 0.9013 0.8440 0.8346
M6 0.8783 0.9579 0.9410 0.9863 0.9396
M7 0.8793 0.9532 0.9452 0.9308 0.9477
M8 0.8959 0.9558 0.9640 0.9899 0.8981
M9 0.9035 0.9528 0.9618 0.9332 0.8865
M10 0.8129 0.9354 0.9029 0.9491 0.9099
M11 0.9119 0.9667 0.9671 0.9759 0.9682
M12 0.9580 0.9942 0.9893 0.9939 0.9754
M13 0.9713 0.9822 0.9753 0.9871 0.9557
ST-M 0.9434 0.9937 0.9785 0.9852 0.8532
ND=Not determined due to insufﬁcient data points; ST-M=Glucophage (standard metformin tablet).
Development of extended release matrix tablets of two drugs 89M13) or Hixson-Crowell model (R2 = 0.9491–0.9899, for M6,
M8, M8, M10, M11, M13). This current study conﬁrms pre-
vious ﬁndings that drug solubility affects drug dissolution,
kinetics and mechanism of drug release from matrix tablet pre-
parations (Li et al., 2008; Chakraborty et al., 2009; Prasanthi
et al., 2010). First order kinetics refers to drug release which
is concentration-dependent while the Higuchi model is used
to describe drug dissolution from several types of modiﬁed
release pharmaceutical dosage forms, including matrix tablets
and some transdermal systems (Singhvi and Singh, 2011).
The Hixson-Crowell model describes drug release from dosage
forms including tablets, whereby there is a change in surface
area and diameter of the dosage form in dissolution media.
Drug dissolution in this model occurs in planes which are par-
allel to the drug surface if the tablet dimensions diminish pro-
portionally; in a manner that the initial geometrical form is
kept constant at all times (Hixson and Crowell, 1931). Drug
release from most of the extended release tablet formulations
of diclofenac and metformin was by Fickian diffusion ordiffusion-controlled release (ﬁrst order or Higuchi model)
while drug release from the remaining tablet formulations
occurred by anomalous or non-Fickian diffusion.
4. Conclusions
Results from the study have shown that light grade cashew
gum powder possesses the requisite physicochemical properties
for use as a direct compression excipient. Extended release
matrix tablets of diclofenac sodium and metformin HCl were
successfully produced using various combinations/blends of
three hydrophilic polymers. Xanthan gum containing matrix
tablets of the two drugs exhibited enhanced swelling and
extended drug release. Drug release from highly water-soluble
metformin occurred over a shorter time period than the poorly
water-soluble diclofenac sodium. The study emphasizes the
complex nature of a pharmaceutical formulation and that
there is no such thing as a universal formulation and each drug
must be considered on a case-by-case basis.
90 K. Ofori-Kwakye et al.Acknowledgement
The authors gratefully acknowledge the technical assistance of
Technicians of the Department of Pharmaceutics, KNUST,
Ghana. Our sincere thanks go to the Management and Staff
of Bodokrom Cashew Plantation, Bodokrom, Ghana, for
providing cashew gum for the study.
References
Aguilar-Dı´az, J.E., Garcı´a-Montoya, E., Pe´rez-Lozano, P., Sun˜e-
Negre, J.M., Min˜arro, M., Tico´, J.R., 2009. The use of the SeDeM
Diagram expert system to determine the suitability of diluents-
disintegrants for direct compression and their use in formulation of
ODT. Eur. J. Pharm. Biopharm. 73 (3), 414–423.
Ali, A., Iqbal, M., Akhtar, N., Khan, H.M., Ullah, A., Uddin, M.,
Khan, M.T., 2013. Assessment of xanthan gum based sustained
release matrix tablets containing highly water-soluble propranolol
HCl. Acta Pol. Pharm. 70 (2), 283–289.
Aulton, M.E., 2007. Pharmaceutics: The Design and Manufacture of
Medicines, third ed. Churchill Livingstone, London.
Bakre, L.G., Jaiyeoba, K.T., 2009. Evaluation of a new tablet
disintegrant from dried pods of Abelmuscus esculentus L. (okra).
Asian J. Pharm. Clin. Res. 2 (3), 82–91.
Baviskar, D., Sharma, R., Jain, D., 2013. Modulation of drug release
by utilizing pH-independent matrix system comprising water
soluble drug verapamil hydrochloride. Pak. J. Pharm. Sci. 26 (1),
137–144.
Chakraborty, S., Khandai, M., Sharma, A., Niranjan Patra, C.H.,
Jagannath Patro, V., Kumar Sen, K., 2009. Effects of drug
solubility on the release kinetics of water soluble and insoluble
drugs from HPMC based matrix formulations. Acta Pharm. 59,
313–323. http://dx.doi.org/10.2478/v10007-009-0025-8.
Chivate, A.A., Poddar, S.S., Abdul, S., Savant, G., 2008. Evaluation
of Sterculia foetida gum as controlled release excipient. AAPS
PharmSciTech 9, 197–204. http://dx.doi.org/10.1208/s12249-008-
9039-7.
Colombo, P., Bettini, R., Santi, P., Peppas, N.A., 2000. Swellable
matrices for controlled drug delivery: gel-layer behaviour, mecha-
nisms and optimal performance. Pharm. Sci. Technol. Today 3 (6),
198–204. http://dx.doi.org/10.1016/S1461-5347(00)00269-8.
Das, N. G., Das, S. K., 2003. Controlled-release of oral dosage forms.
Formulation, Fill & Finish, pp. 10–16. <www. Pharmtech.com>.
Dastidar, S.G., Ganguly, K., Chaudhuri, K., Chakrabarty, A.N.,
2000. The anti-bacterial action of diclofenac shown by inhibition of
DNA synthesis. Int. J. Antimicrob. Ag. 14, 249–251.
Fung, L.K., Saltzman, W.M., 1997. Polymeric implants for cancer
chemotherapy. Adv. Drug Deliv. Rev. 26, 209–230.
Gibaldi, M., Feldman, S., 1967. Establishment of sink conditions in
dissolution rate determinations – theoretical considerations and
application to nondisintegrating dosage forms. J. Pharm. Sci. 56,
1238–1242.
Hentzschel, C.M., Sakmann, A., Leopold, C.S., 2012. Comparison of
traditional and novel tableting excipients: physical and compaction
properties. Pharm. Dev. Technol. 17, 649–653.
Higuchi, T., 1963. Mechanism of sustained action medication:
theoretical analysis of rate of release of solid drugs dispersed in
solid matrices. J. Pharm. Sci. 52, 1145–1148.
Hixson, A.W., Crowell, J.H., 1931. Dependence of reaction velocity
upon surface and agitation: theoretical considerations. Ind. Eng.
Chem. 23, 923–931.
Kamboj, S., Gupta, G. D., Oberoy, J., 2009. Matrix tablets: An
important tool for oral controlled-release dosage forms – A review.
Pharminfo.net 7.
Korsmeyer, R.W., Gurny, R., Doelker, E., Buri, P., Peppas, N.A.,
1983. Mechanism of solute release from porous hydrophilicpolymers. Int. J. Pharm. 15, 25–35. http://dx.doi.org/10.1016/
0378-5173(83)90064-9.
Li, H., Hardy, R.J., Gu, X., 2008. Effect of drug solubility on polymer
hydration and drug dissolution from polyethylene oxide (PEO)
matrix tablets. AAPS PharmSciTech. 9 (2), 437–443. http://
dx.doi.org/10.1208/s12249-008-9060-x.
Maciel, J.S., Paula, H.C.B., Miranda, M.A.R., Sasaki, J.M., de Paula,
R.C.M., 2006. Reacetylated chitosan/cashew gum gel: preliminary
study for potential utilization as drug release matrix. J. Appl.
Polym. Sci. 99 (1), 326–334.
Mfoafo, K.A., 2013. Evaluation of cashew gum as a direct compres-
sion excipient for controlled drug delivery using diclofenac sodium
and metformin hydrochloride as model drugs (MPhil
(Pharmaceutics) thesis). Kwame Nkrumah University of Science
and Technology, Kumasi, Ghana, p. 182.
Narasimharao, R., Anusha Reddy, M., Swetha Reddy, N.,
Divyasagar, P., Keerthana, K., 2011. Design and evaluation of
metformin hydrochloride extended release tablets by direct com-
pression. IJRPBS 2, 1118–1133.
Nussinovitch, A., 2009. Major plant exudates of the world. In: Plant
Gum Exudates of the World. CRC Press.
Odeku, O.A., 2005. Assessment of Albizia zygia gum as a binding
agent in tablet formulations. Acta Pharm. 55, 263–276.
Ofori-Kwakye, K., Asantewaa, Y., Kipo, S.L., 2010. Physicochemical
and binding properties of cashew tree gum in metronidazole tablet
formulations. Int. J. Pharm. Pharm. Sci. 2 (Suppl. 4), 105–109.
Ofori-Kwakye, K., Obese, E., Boakye-Gyasi, E., 2013. Formulation
and in-vitro evaluation of sustained release diclofenac sodium
matrix tablets using blends of cashew gum, xanthan gum and
hydroxypropylmethylcellulose as hydrophilic drug release modi-
ﬁers. IJNDD 5 (4), 187–197.
Peppas, N.A., 1985. Analysis of Fickian and non-Fickian drug release
from polymers. Pharm. Acta Helv. 60 (4), 110–111.
Pe´rez-Lozano, P., Sun˜e´-Negre, J.M., Min˜arro, M., Roig, M., Fuster,
R., Garcı´a-Montoya, E., Herna´ndez, C., Ruhı´, R., Tico´, J.R., 2006.
A new expert systems (SeDeM diagram) for control batch powder
formulation and preformulation drug products. Eur. J. Pharm.
Biopharm. 64 (3), 351–359.
Pharmacopoeia, British., 2012. British Pharmacopoeia Commission.
Her Majesty’s Stationery Ofﬁce, London.
Prasanthi, N.L., Manikiran, S.S., Rama Rao, N., 2010. Effect of
solubility of the drug on the release kinetics from hydrophilic
matrices. Int. J. PharmTech. Res. 2 (4), 2506–2511.
Singhvi, G., Singh, M., 2011. Review: in-vitro drug release character-
ization models. IJPSR 2, 1–8.
Staniforth, J., 2002. Powder ﬂow. In: Aulton, M.E. (Ed.),
Pharmaceutics – the Science of Dosage form Design, second ed.
Churchill Livingstone, London, pp. 197–210.
Sudha, B.S., Sridhar, B.K., Srinatha, A., 2010. Modulation of
tramadol release from a hydrophilic matrix: implications of
formulations and processing variables. AAPS PharmSciTech II,
433–440.
Sun˜e´-Negre, J.M., Pe´rez-Lozano, P., Min˜arro, M., Roig, M., Fuster,
R., Herna´ndez, C., Ruhı´, R., Garcı´a-Montoya, E., Tico´, J.R., 2008.
Application of the SeDeM diagram and a new mathematical
equation in the design of direct compression tablet formulation.
Eur. J. Pharm. Biopharm. 69 (3), 1029–1039.
Sun˜e-Negre, J.M., Garcı´a-Montoya, E., Pe´rez-Lozano, P., Aguilar-
Dı´az, J.E., Carreras, M.R., Garcia, R.F., Carmona, M.M., Tico-
Grau, J.R., 2011. SeDeM diagram: a new expert system for the
formulation of drugs in solid form. In: Vizureanu P. (Ed.), Expert
Systems for Human, Materials and Automation, InTech. <http://
www.intechopen.com/books/expert-systems-for-human-materials-
and-automation/sedem-diagram-anew-expert-system-for-the-
formulation-of-drugs-in-solid-form> [ISBN 978-953-307-334-7].
Thakkar, V.T., Shah, P.A., Soni, T.G., Parmar, M.Y., Gohel, M.C.,
Gandhi, T.R., 2009. Goodness-of-ﬁt model-dependent approach
Development of extended release matrix tablets of two drugs 91for release kinetics of levoﬂoxacin hemihydrates ﬂoating tablet.
Dissolut. Technol., 35–39
Thoorens, G., Krier, F., Leclercq, B., Carlin, B., Evrard, B., 2014.
Microcrystalline cellulose, a direct compression binder in a quality
by design environment – a review. Int. J. Pharm. 473 (1), 64–72.
United States Pharmacopoeia and National Formulary, 2007. United
States Pharmacopoeia XXIII: Rockville U.S.P Convention Inc.
Varelas, C.G., Dixon, D.G., Steiner, C., 1995. Zero-order release from
biphasic polymer hydrogels. J. Control. Release 34, 185–192.Vohra, D.D., Pagi, K.S., Rajesh, K.S., 2012. Losartan potassium
loaded sustained release matrix tablets: inﬂuence of various
hydrophilic and hydrophobic polymers on drug release behavior.
J. Pharm. Bioallied Sci. 4 (Suppl 1), S79–80.
Wagner, J.G., 1969. Interpretation of percent dissolved-time plots
derived from in vitro testing of conventional tablets and capsules. J.
Pharm. Sci. 58, 1253–1257.
